For example, the combined use of saxagliptin with the sodium-glucose cotransporter-2 (SGLT-2) inhibitor dapagliflozin has been demonstrated to be more effective than using either agent alone in patients with T2D receiving metformin therapy who have inadequate glycaemic control, without increasing the risk of hypoglycaemia [37]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.